Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Drugs for Treatment of Ulcerative Colitis in IBD

Drugs for Treatment of Ulcerative Colitis in IBD

Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide generation.

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel Disease...

Inflammatory Bowel Disease IV: Pharmacological Management

Inflammatory Bowel Disease IV: Pharmacological Management

Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...

Drugs for Treatment of Diarrhea-Predominant IBS

Drugs for Treatment of Diarrhea-Predominant IBS

Diarrhea-predominant irritable bowel syndrome (IBS-D) is a subtype of IBS characterized primarily by frequent, loose, or watery stools, abdominal pain, and abdominal discomfort. Therapeutic approaches to managing IBS-D include dietary changes, stress management techniques, and pharmaceutical interventions.
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...

Drugs Affecting GI Tract Motility: Antimicrobials as Antidiarrheal Agents

Drugs Affecting GI Tract Motility: Antimicrobials as Antidiarrheal Agents

Acute diarrhea, a common gastrointestinal disturbance, is characterized by the rapid evacuation of fluid stools, leading to an excessive weight in fluid. This condition typically arises from disorders affecting intestinal water and electrolyte transport. It can be triggered by an increased osmotic load within the intestine, excessive secretion of electrolytes and water, mucosal exudation of protein and fluid, or altered intestinal motility. The primary risks of acute diarrhea are dehydration...

Drugs for Treatment of Constipation-Predominant IBS

Drugs for Treatment of Constipation-Predominant IBS

Pharmacological therapies for IBS-C are designed to alleviate abdominal discomfort and enhance bowel function. In patients with IBS-C, fiber supplements may help soften stools and decrease straining, but may also lead to increased gas production and bloating. Osmotic laxatives like milk of magnesia are frequently used to soften stools and increase stool frequency in IBS-C patients. In addition, two drugs approved for use in severe IBS-C adult cases are linaclotide (Linzess) and lubiprostone...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Antibiotics promote susceptibility to <i>C. difficile</i> infection through a CCR5-dependent immune response.

bioRxiv : the preprint server for biology·2026

Same author

The Impact of Fecal Microbiota Transplantation on Host Immunity and Epithelial Restoration Following Clostridioides difficile Infection.

Anaerobe·2026

Same author

CXCR3 ameliorates neutrophil-dependent disease severity in SARS-CoV-2 infection by regulating CD4<sup>+</sup> T cell recruitment.

Frontiers in immunology·2026

Same author

Association of SARS-CoV-2 infection with incident diabetes among U.S. Veterans in a prospective longitudinal cohort.

PloS one·2026

Same author

Breast milk cytokines and infant growth trajectories in a low-income community in Bangladesh.

Pediatric research·2026

Same author

Erysipelothrix rhusiopathiae Prosthetic Joint Infection of the Knee in an Immunocompromised Patient.

Cureus·2026

Search research articles

Related Experiment Video

Updated: May 8, 2026

A Protocol to Characterize the Morphological Changes of Clostridium difficile in Response to Antibiotic Treatment

A Protocol to Characterize the Morphological Changes of Clostridium difficile in Response to Antibiotic Treatment

Published on: May 25, 2017

New developments in chemotherapeutic options for Clostridium difficile colitis.

Alaina S Ritter¹, William A Petri

¹Division of Infectious Diseases and International Health, Department of Medicine, University of Virginia Health System, Charlottesville, Virginia 22908-1340, USA.

Current Opinion in Infectious Diseases

|August 29, 2013

Summary

New treatments for Clostridium difficile infections (CDIs) show promise for cure and preventing relapse. While standard therapies remain, emerging options like fidaxomicin and investigational drugs offer hope for improved outcomes.

More Related Videos

Fecal Microbiota Transplantation via Colonoscopy for Recurrent C. difficile Infection

Fecal Microbiota Transplantation via Colonoscopy for Recurrent C. difficile Infection

Published on: December 8, 2014

Related Experiment Videos

Last Updated: May 8, 2026

A Protocol to Characterize the Morphological Changes of Clostridium difficile in Response to Antibiotic Treatment

A Protocol to Characterize the Morphological Changes of Clostridium difficile in Response to Antibiotic Treatment

Published on: May 25, 2017

Fecal Microbiota Transplantation via Colonoscopy for Recurrent C. difficile Infection

Fecal Microbiota Transplantation via Colonoscopy for Recurrent C. difficile Infection

Published on: December 8, 2014

Area of Science:

Infectious Diseases
Microbiology
Pharmacology

Background:

Clostridium difficile infections (CDIs) present a growing healthcare challenge due to rising incidence.
Standard therapies for CDI exhibit suboptimal response rates, necessitating novel treatment approaches.

Purpose of the Study:

To review current chemotherapeutic treatment options for primary Clostridium difficile infections (CDIs).
To discuss emerging therapies for preventing CDI recurrence and relapse.

Main Methods:

Literature review of recent studies on CDI treatment.
Analysis of clinical trial data for novel therapeutic agents.
Evaluation of in-vitro activity of various antimicrobial compounds.

Main Results:

Metronidazole and vancomycin are standard for mild and severe CDI, respectively.
Fidaxomicin demonstrates reduced recurrence rates compared to vancomycin.
Rifaximin shows potential in salvage therapy for recurrent CDI.
Several agents including tigecycline, doxycycline, and LFF571 are under investigation.
Monoclonal antitoxin antibodies are in phase 3 trials for CDI relapse prevention.

Conclusions:

Promising new treatments for Clostridium difficile are under development.
Further research is essential to confirm the efficacy of novel therapies for CDI cure and relapse prevention.